Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.

Autor: Eichner R; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany., Heider M; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany., Fernández-Sáiz V; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., van Bebber F; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany., Garz AK; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Lemeer S; Department of Proteomics and Bioanalytics, Technische Universität München, Freising, Germany., Rudelius M; Institute of Pathology, Universität Würzburg, Würzburg, Germany.; Comprehensive Cancer Center Mainfranken, Universität Würzburg, Würzburg, Germany., Targosz BS; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany., Jacobs L; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany., Knorn AM; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany., Slawska J; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany., Platzbecker U; Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl-Gustav-Carus, Technische Universität, Dresden, Germany., Germing U; Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany., Langer C; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Knop S; Division of Hematology and Medical Oncology, Department of Internal Medicine II, Würzburg University Medical Center, Würzburg, Germany., Einsele H; Division of Hematology and Medical Oncology, Department of Internal Medicine II, Würzburg University Medical Center, Würzburg, Germany., Peschel C; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Haass C; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.; Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany., Keller U; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Schmid B; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany., Götze KS; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Kuster B; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Proteomics and Bioanalytics, Technische Universität München, Freising, Germany.; Center for Integrated Protein Science Munich (CIPSM), Freising, Germany., Bassermann F; Department of Medicine III, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jazyk: angličtina
Zdroj: Nature medicine [Nat Med] 2016 Jul; Vol. 22 (7), pp. 735-43. Date of Electronic Publication: 2016 Jun 13.
DOI: 10.1038/nm.4128
Abstrakt: Immunomodulatory drugs (IMiDs), such as thalidomide and its derivatives lenalidomide and pomalidomide, are key treatment modalities for hematologic malignancies, particularly multiple myeloma (MM) and del(5q) myelodysplastic syndrome (MDS). Cereblon (CRBN), a substrate receptor of the CRL4 ubiquitin ligase complex, is the primary target by which IMiDs mediate anticancer and teratogenic effects. Here we identify a ubiquitin-independent physiological chaperone-like function of CRBN that promotes maturation of the basigin (BSG; also known as CD147) and solute carrier family 16 member 1 (SLC16A1; also known as MCT1) proteins. This process allows for the formation and activation of the CD147-MCT1 transmembrane complex, which promotes various biological functions, including angiogenesis, proliferation, invasion and lactate export. We found that IMiDs outcompete CRBN for binding to CD147 and MCT1, leading to destabilization of the CD147-MCT1 complex. Accordingly, IMiD-sensitive MM cells lose CD147 and MCT1 expression after being exposed to IMiDs, whereas IMiD-resistant cells retain their expression. Furthermore, del(5q) MDS cells have elevated CD147 expression, which is attenuated after IMiD treatment. Finally, we show that BSG (CD147) knockdown phenocopies the teratogenic effects of thalidomide exposure in zebrafish. These findings provide a common mechanistic framework to explain both the teratogenic and pleiotropic antitumor effects of IMiDs.
Databáze: MEDLINE
Externí odkaz: